A Phase 3 interventional study of Rivaroxaban (Xarelto, BAY59-7939) and Enoxaparin overlapping with and followed by VKA in Pulmonary Embolism, sponsored by Bayer. Completed at 305 sites in 39 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-02-27.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing rivaroxaban in Pulmonary Embolism — 4 open to participants now, 6 under way, 2 of them phase 3. Rivaroxaban · Pulmonary Embolism.
Among the 20 studies testing rivaroxaban in Pulmonary Embolism, this one is the 4th largest by enrollment, is one of 2 that started in 2007, is one of 7 in phase 3, and was the 1st registered.
832 studies on the registry are indexed under Pulmonary Embolism; 171 are open to participants now.
Browse Pulmonary Embolism studies →4 of the 20 studies testing rivaroxaban in Pulmonary Embolism are open now, in 8 countries. Recruiting first, the newest first:
Prof. Stavros Konstantinides, MD · Sites in Austria, Germany
Ages 18–85
Medical University of Gdansk · Sites in Poland
Ages 18+
University Hospital, Angers · Sites in France
Ages 18+
Drahomir Aujesky · Sites in Belgium, Canada, France and 2 more countries
Ages 18+
By country, each count listing its studies:
Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 129 Pulmonary Embolism studies recruiting now, 109 (84%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 8 · Phase 4 6
First in 2004; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4,833 is above the median of 174 across 429 interventional studies indexed under Pulmonary Embolism.
Median enrollment 241 across the 20 interventional studies. Of the 14 that completed or were terminated, 7 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 20 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
15 studies in Pulmonary Embolism by Bayer: none open now, none under way, none of them phase 3. Of 14 finished, 4 (29%) have results posted.
Among the 15 studies in Pulmonary Embolism by Bayer, this one is one of 2 that started in 2007, is one of 4 in phase 3, and was the 1st registered.
Bayer’s Pulmonary Embolism studies by the year they started, since 2004.
2 of the studies testing rivaroxaban in Pulmonary Embolism that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06611319Phase 3Prof. Stavros Konstantinides, MDENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty | 2027-03 |
| NCT03129555Herlev and Gentofte HospitalThe Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE) | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies testing rivaroxaban in Pulmonary Embolism, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bayer’s 15 in Pulmonary Embolism:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, open-label, assessor-blind, event-driven, non-inferiority program for efficacy with a study treatment duration of 3, 6 or 12 months in patients with confirmed acute symptomatic pulmonary embolism (PE) with or without symptomatic Deep-Vein Thrombosis (DVT) (Einstein-PE).
Within the US 'Johnson \& Johnson Pharmaceutical Research \& Development, L.L.C.' is sponsor.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants received 15 mg rivaroxaban (oral) twice daily (b.i.d.) for 3 weeks, followed by 20 mg once daily (o.d.)
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Participants received enoxaparin (subcutaneous) 1.0 mg/kg b.i.d. for minimal 5 days, plus vitamin K antagonist (VKA) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 - 3.0)
Drug: Enoxaparin overlapping with and followed by VKA
During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.
Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 hr before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.
Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries.
Time frame: 3-, 6-, or 12-month study treatment period
Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality Until the Intended End of Study Treatment
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries.
Time frame: 3-, 6-, or 12-month study treatment period
Percentage of Participants With an Event for Net Clinical Benefit 1 Until the Intended End of Study Treatment
Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE, and major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.
Time frame: 3-, 6-, or 12-month study treatment period
Percentage of Participants With Recurrent PE Until the Intended End of Study Treatment
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.
Time frame: 3-, 6- or 12-month study treatment period
Percentage of Participants With Recurrent DVT Until the Intended End of Study Treatment
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries.
Time frame: 3-, 6- or 12-month study treatment period
Percentage of Participants With Clinically Relevant Bleeding, Treatment-emergent (Time Window: Until 2 Days After Last Dose)
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Clinically relevant bleeding included major bleeding (overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of activities of daily life.
Time frame: 3-, 6- or 12-month study treatment period
Percentage of Participants With All Deaths
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either autopsy, results/films/images of confirmatory testing, and/or case summaries.
Time frame: 3-, 6- or 12-month study treatment period
Percentage of Participants With Other Vascular Events, On-treatment (Time Window: Until 1 Day After Last Dose)
All pre-defined vascular events (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, unstable angina, ischemic stroke, transient ischemic attack, non-central nervous system systemic embolism or vascular death) were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based results/films/images of confirmatory testing, and/or case summaries.
Time frame: 3-, 6- or 12-month study treatment period
Percentage of Participants With the Individual Components of Efficacy Outcomes Until the Intended End of Study Treatment
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death.
Time frame: 3-, 6- or 12-month study treatment period
Percentage of Participants With Symptomatic Recurrent VTE (i.e. the Composite of Recurrent DVT or Fatal or Non-fatal PE) During Observational Period
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries.
Time frame: Up to 30 days after the last intake of study medication
Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality During Observational Period
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries.
Time frame: Up to 30 days after the last intake of study medication
Percentage of Participants With an Event for Net Clinical Benefit 1 During Observational Period
Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE, and major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.
Time frame: Up to 30 days after the last intake of study medication
Percentage of Participants With Recurrent DVT During Observational Period
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries.
Time frame: Up to 30 days after the last intake of study medication
Percentage of Participants With the Individual Components of Efficacy Outcomes During Observational Period
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death.
Time frame: Up to 30 days after the last intake of study medication
Participants with confirmed acute symptomatic pulmonary embolism (PE) with or without symptomatic deep vein thrombosis (DVT) were recruited at specialized study sites.
| Milestone | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Started | 2420 | 2413 |
| Participants received treatment | 2412 | 2405 |
| Completed | 2001 | 1954 |
| Not completed | 419 | 459 |
| Withdrew: Death | 29 | 21 |
| Withdrew: Study terminated by sponsor | 125 | 132 |
| Withdrew: Site closed by investigator | 0 | 1 |
| Withdrew: Did not take study treatment | 7 | 8 |
| Withdrew: Adverse event | 111 | 92 |
| Withdrew: Protocol violation | 23 | 30 |
| Withdrew: Withdrawal by subject | 66 | 118 |
| Withdrew: Lack of efficacy | 1 | 4 |
| Withdrew: Lost to follow-up | 8 | 10 |
| Withdrew: Protocol driven decision point | 1 | 3 |
| Withdrew: Physician decision | 7 | 18 |
| Withdrew: Clinical endpoint reached | 26 | 13 |
| Withdrew: Technical problems | 3 | 1 |
| Withdrew: Participant convenience | 12 | 8 |
| Milestone | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Started | 2206 | 2197 |
| Completed | 2165 | 2156 |
| Not completed | 41 | 41 |
| Withdrew: Protocol violation | 0 | 2 |
| Withdrew: Withdrawal by subject | 9 | 5 |
| Withdrew: Lost to follow-up | 1 | 11 |
| Withdrew: Death | 27 | 20 |
| Withdrew: Study terminated by sponsor | 3 | 1 |
| Withdrew: Protocol driven decision point | 0 | 1 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Technical problems | 0 | 1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment | 2.1 | 1.8 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality Until the Intended End of Study Treatment | 4.0 | 3.4 |
Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE, and major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Percentage of Participants With an Event for Net Clinical Benefit 1 Until the Intended End of Study Treatment | 3.4 | 4.0 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Percentage of Participants With Recurrent PE Until the Intended End of Study Treatment | 1.4 | 1.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Percentage of Participants With Recurrent DVT Until the Intended End of Study Treatment | 0.7 | 0.8 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Clinically relevant bleeding included major bleeding (overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of activities of daily life.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Percentage of Participants With Clinically Relevant Bleeding, Treatment-emergent (Time Window: Until 2 Days After Last Dose) | 10.3 | 11.4 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either autopsy, results/films/images of confirmatory testing, and/or case summaries.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| All post-randomization | 2.6 | 2.1 |
| Treatment-emergent (time window: 2 days) | 1.2 | 0.8 |
| Treatment-emergent (time window: 7 days) | 1.5 | 1.1 |
All pre-defined vascular events (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, unstable angina, ischemic stroke, transient ischemic attack, non-central nervous system systemic embolism or vascular death) were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based results/films/images of confirmatory testing, and/or case summaries.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Percentage of Participants With Other Vascular Events, On-treatment (Time Window: Until 1 Day After Last Dose) | 1.5 | 1.5 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Death (PE) | 0.1 | 0.04 |
| Death (PE cannot be excluded) | 0.3 | 0.2 |
| Symptomatic PE and DVT | 0.0 | 0.1 |
| Symptomatic recurrent PE only | 1.0 | 0.8 |
| Symptomatic recurrent DVT only | 0.7 | 0.7 |
| Death (bleeding) | 0.2 | 0.2 |
| Death (cardiovascular) | 0.4 | 0.1 |
| Death (other) | 1.3 | 1.5 |
| Major bleeding | 1.4 | 2.4 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Percentage of Participants With Symptomatic Recurrent VTE (i.e. the Composite of Recurrent DVT or Fatal or Non-fatal PE) During Observational Period | 0.9 | 0.7 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality During Observational Period | 2.1 | 1.5 |
Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE, and major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Percentage of Participants With an Event for Net Clinical Benefit 1 During Observational Period | 1.2 | 1.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Percentage of Participants With Recurrent DVT During Observational Period | 0.3 | 0.1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Death (PE) | 0.09 | 0 |
| Death (PE cannot be excluded) | 0 | 0.05 |
| Symptomatic PE and DVT | 0.09 | 0 |
| Symptomatic recurrent PE only | 0.5 | 0.5 |
| Symptomatic recurrent DVT only | 0.2 | 0.1 |
| Death (bleeding) | 0.09 | 0.09 |
| Death (cardiovascular) | 0.3 | 0.05 |
| Death (other) | 0.8 | 0.7 |
| Major bleeding | 0.3 | 0.5 |
Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding (associated with 2 g/dL or greater fall in hemoglobin, leading to transfusion of ≥2 units, occurring in a critical site or contributing to death), cardiovascular death, myocardial infarction, stroke, and non CNS (central nervous system) systemic embolism. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound (DVT), venography (DVT), spiral CT scanning (PE), pulmonary angiography (PE), ventilation/perfusion lung scan (PE), lung scintigraphy (PE), autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Percentage of Participants With an Event for Net Clinical Benefit 2 Until the Intended End of Study Treatment | 4.5 | 4.8 |
Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding (associated with 2 g/dL or greater fall in hemoglobin, leading to transfusion of ≥2 units, occurring in a critical site or contributing to death), cardiovascular death, myocardial infarction, stroke, and non CNS (central nervous system) systemic embolism. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound (DVT), venography (DVT), spiral CT scanning (PE), pulmonary angiography (PE), ventilation/perfusion lung scan (PE), lung scintigraphy (PE), autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Percentage of Participants With an Event for Net Clinical Benefit 2 During Observational Period | 1.5 | 1.4 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | — | 504/2,412 (20.9%) | 1,053/2,412 (43.7%) |
| Enoxaparin/VKA | — | 495/2,405 (20.6%) | 1,065/2,405 (44.3%) |
| Event | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| Chest painGeneral disorders | 21/2412 | 27/2405 |
| PneumoniaInfections and infestations | 22/2412 | 21/2405 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 17/2412 | 13/2405 |
| AnaemiaBlood and lymphatic system disorders | 14/2412 | 6/2405 |
| SepsisInfections and infestations | 13/2412 | 2/2405 |
| Ischaemic strokeNervous system disorders | 13/2412 | 5/2405 |
| Atrial fibrillationCardiac disorders | 8/2412 | 11/2405 |
| HaematuriaRenal and urinary disorders | 8/2412 | 11/2405 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 9/2412 | 11/2405 |
| Acute myocardial infarctionCardiac disorders | 6/2412 | 10/2405 |
| Event | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA |
|---|---|---|
| EpistaxisRespiratory, thoracic and mediastinal disorders | 229/2412 | 205/2405 |
| HeadacheNervous system disorders | 196/2412 | 177/2405 |
| NasopharyngitisInfections and infestations | 188/2412 | 195/2405 |
| Chest painGeneral disorders | 179/2412 | 181/2405 |
| CoughRespiratory, thoracic and mediastinal disorders | 160/2412 | 179/2405 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 172/2412 | 162/2405 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 156/2412 | 147/2405 |
| ConstipationGastrointestinal disorders | 146/2412 | 141/2405 |
| Back painMusculoskeletal and connective tissue disorders | 87/2412 | 134/2405 |
| ContusionInjury, poisoning and procedural complications | 95/2412 | 133/2405 |
| Age, Continuous(Years) | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA | Total |
|---|---|---|---|
| Mean | 57.9 ± 17.3 | 57.5 ± 17.2 | 57.7 ± 17.3 |
| Age, Customized(Participants) | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA | Total |
|---|---|---|---|
| 18 - < 40 years | 410 | 432 | 842 |
| 40 - < 60 years | 794 | 779 | 1573 |
| 60 - < 75 years | 740 | 754 | 1494 |
| ≥ 75 years | 475 | 448 | 923 |
| Sex: Female, Male(Participants) | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin/VKA | Total |
|---|---|---|---|
| Female | 1309 | 1247 | 2556 |
| Male | 1110 | 1166 | 2276 |
Showing the first 100 of 305 sites across 39 countries. Choose a country and city above to see the rest.
The record gives a start of Mar 2007, a primary completion of Sep 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2013, 1 year 4 months after primary completion. A results delay was requested in Dec 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rivaroxaban